BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23349954)

  • 21. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.
    Lee CC; Lee CH; Hong MY; Hsieh CC; Tang HJ; Ko WC
    J Microbiol Immunol Infect; 2018 Aug; 51(4):519-526. PubMed ID: 28698042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].
    Angel Díaz M; Ramón Hernández J; Martínez-Martínez L; Rodríguez-Baño J; Pascual A;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):503-10. PubMed ID: 19329230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
    Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
    Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk factors of community-onset extended-spectrum β-lactamase Escherichia coli and Klebsiella pneumoniae bacteraemia: an 11-year population-based case-control-control study in Denmark.
    Richelsen R; Smit J; Laxsen Anru P; Schønheyder HC; Nielsen H
    Clin Microbiol Infect; 2021 Jun; 27(6):871-877. PubMed ID: 32781243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
    Kiratisin P; Apisarnthanarak A; Laesripa C; Saifon P
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2818-24. PubMed ID: 18505851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.
    Yang YS; Ku CH; Lin JC; Shang ST; Chiu CH; Yeh KM; Lin CC; Chang FY
    J Microbiol Immunol Infect; 2010 Jun; 43(3):194-9. PubMed ID: 21291846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella pneumoniae in 11 Spanish hospitals (2004)].
    Diestra K; Coque TM; Miró E; Oteo J; Nicolau CJ; Campos J; Moyá B; Curiao T; Pérez-Vázquez M; Cantón R; Oliver A; Navarro F;
    Enferm Infecc Microbiol Clin; 2008; 26(7):404-10. PubMed ID: 18842234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland.
    Kuster SP; Hasse B; Huebner V; Bansal V; Zbinden R; Ruef C; Ledergerber B; Weber R
    Infection; 2010 Feb; 38(1):33-40. PubMed ID: 20108162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of extended-spectrum beta-lactamase-producing
    Siriphap A; Kitti T; Khuekankaew A; Boonlao C; Thephinlap C; Thepmalee C; Suwannasom N; Khoothiam K
    Front Cell Infect Microbiol; 2022; 12():955774. PubMed ID: 36004324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteremia Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Vientiane, Lao PDR: A 5-Year Study.
    Chang K; Rattanavong S; Mayxay M; Keoluangkhot V; Davong V; Vongsouvath M; Luangraj M; Simpson AJH; Newton PN; Dance DAB
    Am J Trop Med Hyg; 2020 May; 102(5):1137-1143. PubMed ID: 32157990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
    Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
    Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand .
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Jan; 29(1):80-2. PubMed ID: 18171194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli.
    Hsieh CJ; Shen YH; Hwang KP
    J Microbiol Immunol Infect; 2010 Jun; 43(3):240-8. PubMed ID: 21291853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.